510(k)
K211499: 23andMe PGS Genetic Risk Report for Hereditary Prostate Cancer (HOXB13-Related)
FDA 510(k) · 23AndMe, Inc. · decided Jan 6, 2022
Key facts
| 510(k) number | K211499 |
|---|---|
| Device name | 23andMe PGS Genetic Risk Report for Hereditary Prostate Cancer (HOXB13-Related) |
| Applicant | 23AndMe, Inc. |
| Product code | QAZ |
| Date received | May 14, 2021 |
| Decision date | Jan 6, 2022 |
| Decision | Substantially equivalent (SESE) |
| Submission type | Traditional |
| Review panel | Medical Genetics |
| Medical specialty | Medical Genetics |
At a glance
- None MAUDE adverse event reports
- None Recall events
- None UDI device identifiers (GUDID)
- 1–9 Predicate devices cited
- None Later submissions citing this device
- 1–9 510(k)s with this product code
- Yes 510(k) summary on file
- No 510(k) statement on file
- Not listed On the FDA AI-enabled device list
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
Reading a 510(k)
- Decision
- SESE means the FDA found the device substantially equivalent to its predicate, so it may be marketed in the United States.
- Predicates
- Each clearance cites one or more legally marketed devices; the chain of predicates shows where a technology came from.
- Product code
- The three-letter code sets the device type, class and regulation, and groups competing clearances.
- Summary or statement
- Applicants file either a 510(k) summary of the safety and effectiveness information or a statement that it is available on request.
About 510(k) premarket notifications
A 510(k) is a premarket submission made to the FDA to demonstrate that a device is substantially equivalent to a legally marketed predicate device.
Source: U.S. Food and Drug Administration (FDA), 510(k) Premarket Notification database · Source date: